- Home
- ALX vs KRSA Comparison
ALX vs KRSA Comparison
Compare ALX & KRSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | KRSA |
|---|---|---|
| Founded | 1928 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALX | KRSA |
|---|---|---|
| Price | $248.37 | $31.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.00 |
| AVG Volume (30 Days) | 24.1K | ★ 112.3K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | ★ 7.28% | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ 31.15 | N/A |
| Revenue | ★ $213,183,000.00 | $2,074,000.00 |
| Revenue This Year | $14.78 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.93 | ★ N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $201.28 | $29.03 |
| 52 Week High | $289.43 | $37.27 |
Technical Indicators
Market Signals| Indicator | ALX | KRSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 45.24 |
| Support Level | $242.66 | $29.98 |
| Resistance Level | $251.32 | $36.30 |
| Average True Range (ATR) | 4.70 | 2.56 |
| MACD | 1.49 | 0.04 |
| Stochastic Oscillator | 85.65 | 34.98 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About KRSA Korsana Biosciences Inc. Common Stock
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.